1422-Mechanisms of First-Line Drug Resistance in HCC
This review paper examine how epigenetic regulation—specifically non-coding RNA, DNA methylation, and histone modification—drives resistance to sorafenib and lenvatinib in liver cancer. Research highlights that hepatocellular carcinoma cells survive targeted therapy by rewiring metabolic pathways, expanding cancer stem cell populations, and evading programmed cell death. The text details how abnormal transport processes, such as exosome signaling and drug efflux, further reduce the efficacy of these first-line treatments. By identifying these specific molecular mechanisms, the authors suggest…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.